You can buy or sell Mesoblast and other stocks, options, ETFs, and crypto commission-free!
Mesoblast Limited American Depositary Shares, also called Mesoblast, is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target the cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. Read More The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.
Melbourne, Victoria (VIC)
52 Week High
52 Week Low
Markets InsiderMar 13
Mesoblast Features at Upcoming U.S. Investor Conferences
NEW YORK and MELBOURNE, Australia, March 13, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced it will be featured at two investor conferences in March: Oppenheimer 29th Annual Healthcare Conference in New York on Wednesday, March 20, 2019 at 1:00 p.m. ET. The Alliance for Regenerative Medicine’s Seventh Annual Cell & Gene Therapy Investor Day in New York on Thursday, March 21, 2019 at 4:15 p.m. ET. About Mesoblast Mesoblast Limited (ASX: MSB; Nasdaq: MESO) is a world...
Simply Wall StMar 10
Before You Buy Mesoblast Limited (ASX:MSB), Consider Its Volatility
If you’re interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio.
Stock Price, News, & Analysis for Mesoblast
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing M...
Expected May 29, After Hours